AI MARKET SCANNING

Mineralys Therapeutics Inc

📅 Next Catalyst: Nov 04, 2026 (🌙 Close) 🏛️ NASDAQ 📁 Health Technology 🏭 Biotechnology
AVG HISTORICAL GAP -1.17%
MAX GAP RECORD +9.83%
🔒 PRO INSTITUTIONAL AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡

SENTINEL HISTORICAL GAP VIEWER

// $MLYS
📊 1-YEAR TIMELINE (GAPS PLOTTED) 🔮 SIMULATE SETUP 🔒
Bullish Opening Gap Bearish Opening Gap T-1 Close Baseline

CATALYSTS & GAP HISTORY

Nov 04, 2026 Earnings Release 2026-11-04 (UNDETERMINED) 🔮 UPCOMING 🔒
Aug 11, 2026 Earnings Release 2026-08-11 (AFTER CLOSE)
-8.09%
May 06, 2026 Earnings Release 2026-05-06 (AFTER CLOSE)
-3.12%
Mar 12, 2026 Earnings Release 2026-03-12 (AFTER CLOSE)
-4.37%
Nov 10, 2025 Earnings Release 2025-11-10 (AFTER CLOSE)
-6.04%
Aug 12, 2025 Earnings Release 2025-08-12 (AFTER CLOSE)
-2.96%
May 12, 2025 Earnings Release 2025-05-12 (AFTER CLOSE)
+0.40%
Feb 12, 2025 Earnings Release 2025-02-12 (BEFORE OPEN)
+9.83%

VOLATILITY & GAP BIAS

AVG GAP MOVE 3.5%
Bullish Gaps (2)
Bearish Gaps (7)
Neutral / Flat (5)

QUANTITATIVE LIVE RADAR BLOTTER

Algorithmic execution stream for $MLYS

EXECUTIONS1 LOGS
STATUS🔒 ENCRYPTED
Execution Date Strategy & Setup Direction Execution Range Hold Time Net PnL
2026-10-29 🔒 PRO RADAR ••• x• $•••.•• → $•••.•• 1513m +3.77%
🔒 Real-Time Strategy Telemetry Protected

Exact execution levels, Trailing Stops, and live bot signals are reserved for PRO members.

UNLOCK LIVE RADAR ⚡

📖 Intelligence Summary

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated…

NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗